QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.02
(-16.58%)
SEK 0.02
(-16.58%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.52 Million SEK | 32.24% |
| 2022 | -24.38 Million SEK | -8.71% |
| 2021 | -22.43 Million SEK | 26.42% |
| 2020 | -30.48 Million SEK | -44.44% |
| 2019 | -21.1 Million SEK | -75.13% |
| 2018 | -12.05 Million SEK | -169.74% |
| 2017 | -4.46 Million SEK | -146.57% |
| 2016 | 9.59 Million SEK | 1560.03% |
| 2015 | 578 Thousand SEK | 185.76% |
| 2014 | -674 Thousand SEK | 59.69% |
| 2013 | -1.67 Million SEK | 45.8% |
| 2012 | -3.08 Million SEK | -920.48% |
| 2011 | 376 Thousand SEK | 408.11% |
| 2010 | 74 Thousand SEK | 54.17% |
| 2009 | 48 Thousand SEK | -93.63% |
| 2008 | 753 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.58 Million SEK | 0.0% |
| 2024 Q1 | -3.58 Million SEK | -7.3% |
| 2023 Q4 | -3.34 Million SEK | 0.0% |
| 2023 Q1 | -4.91 Million SEK | 15.94% |
| 2023 FY | -16.52 Million SEK | 32.24% |
| 2023 Q2 | -4.91 Million SEK | 0.0% |
| 2023 Q3 | -3.34 Million SEK | 32.03% |
| 2022 FY | -24.38 Million SEK | -8.71% |
| 2022 Q1 | -5.93 Million SEK | 13.89% |
| 2022 Q2 | -5.41 Million SEK | 8.88% |
| 2022 Q4 | -5.85 Million SEK | 18.56% |
| 2022 Q3 | -7.18 Million SEK | -32.77% |
| 2021 Q2 | -4.49 Million SEK | -17.95% |
| 2021 FY | -22.43 Million SEK | 26.42% |
| 2021 Q4 | -6.89 Million SEK | -43.73% |
| 2021 Q1 | -3.81 Million SEK | 42.81% |
| 2021 Q3 | -4.79 Million SEK | -6.74% |
| 2020 Q3 | -9.5 Million SEK | -63.74% |
| 2020 Q2 | -5.8 Million SEK | -1.01% |
| 2020 FY | -30.48 Million SEK | -44.44% |
| 2020 Q1 | -5.74 Million SEK | 0.5% |
| 2020 Q4 | -6.66 Million SEK | 29.85% |
| 2019 FY | -21.1 Million SEK | -75.13% |
| 2019 Q2 | -3.99 Million SEK | -32.81% |
| 2019 Q1 | -3.01 Million SEK | 50.06% |
| 2019 Q4 | -5.77 Million SEK | 15.07% |
| 2019 Q3 | -6.79 Million SEK | -69.97% |
| 2018 Q1 | -1.16 Million SEK | 7.38% |
| 2018 FY | -12.05 Million SEK | -169.74% |
| 2018 Q4 | -6.02 Million SEK | -278.47% |
| 2018 Q3 | -1.59 Million SEK | 51.18% |
| 2018 Q2 | -3.26 Million SEK | -179.61% |
| 2017 FY | -4.46 Million SEK | -146.57% |
| 2017 Q2 | -1.79 Million SEK | -284.58% |
| 2017 Q3 | -945 Thousand SEK | 47.38% |
| 2017 Q4 | -1.26 Million SEK | -33.33% |
| 2017 Q1 | -467 Thousand SEK | -104.73% |
| 2016 Q1 | -447 Thousand SEK | 16.29% |
| 2016 FY | 9.59 Million SEK | 1560.03% |
| 2016 Q3 | 147 Thousand SEK | 444.44% |
| 2016 Q4 | 9.86 Million SEK | 6612.93% |
| 2016 Q2 | 27 Thousand SEK | 106.04% |
| 2015 Q1 | 958 Thousand SEK | 237.32% |
| 2015 Q2 | 334 Thousand SEK | -65.14% |
| 2015 Q4 | -534 Thousand SEK | -196.67% |
| 2015 FY | 578 Thousand SEK | 185.76% |
| 2015 Q3 | -180 Thousand SEK | -153.89% |
| 2014 Q1 | -241 Thousand SEK | 72.52% |
| 2014 FY | -674 Thousand SEK | 59.69% |
| 2014 Q4 | 284 Thousand SEK | 181.14% |
| 2014 Q3 | -350 Thousand SEK | 4.63% |
| 2014 Q2 | -367 Thousand SEK | -52.28% |
| 2013 FY | -1.67 Million SEK | 45.8% |
| 2013 Q4 | -877 Thousand SEK | -601.14% |
| 2013 Q1 | -439 Thousand SEK | 81.99% |
| 2013 Q2 | -531 Thousand SEK | -20.96% |
| 2013 Q3 | 175 Thousand SEK | 132.96% |
| 2012 Q3 | -522 Thousand SEK | 0.0% |
| 2012 Q4 | -2.43 Million SEK | -366.86% |
| 2012 FY | -3.08 Million SEK | -920.48% |
| 2011 Q2 | 505 Thousand SEK | 0.0% |
| 2011 FY | 376 Thousand SEK | 408.11% |
| 2010 Q2 | 506 Thousand SEK | 0.0% |
| 2010 FY | 74 Thousand SEK | 54.17% |
| 2009 Q2 | -259 Thousand SEK | 0.0% |
| 2009 FY | 48 Thousand SEK | -93.63% |
| 2008 FY | 753 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -0.261% |
| Amniotics AB (publ) | -30.87 Million SEK | 46.476% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -28.804% |
| BioArctic AB (publ) | 229.24 Million SEK | 107.207% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 96.456% |
| Genovis AB (publ.) | 61.5 Million SEK | 126.867% |
| LIDDS AB (publ) | -40.2 Million SEK | 58.904% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 235.779% |
| OncoZenge AB (publ) | -15.9 Million SEK | -3.905% |
| Saniona AB (publ) | -95.81 Million SEK | 82.754% |
| Simris Alg AB (publ) | -37.3 Million SEK | 55.708% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 94.686% |
| AcouSort AB (publ) | -17.08 Million SEK | 3.312% |
| Active Biotech AB (publ) | -45.8 Million SEK | 63.924% |
| Camurus AB (publ) | 431.44 Million SEK | 103.83% |
| Cantargia AB (publ) | -280.02 Million SEK | 94.099% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 21.659% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 85.42% |
| Mendus AB (publ) | -101.61 Million SEK | 83.74% |
| Kancera AB (publ) | -64.88 Million SEK | 74.537% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 406.777% |
| Lipum AB (publ) | -37.17 Million SEK | 55.557% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -36.238% |
| NextCell Pharma AB | -41.95 Million SEK | 60.622% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 95.743% |
| Xintela AB (publ) | -54.08 Million SEK | 69.449% |
| Ziccum AB (publ) | -21.41 Million SEK | 22.833% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -0.762% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 7.677% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 55.429% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 90.804% |
| CombiGene AB (publ) | -35.66 Million SEK | 53.672% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 89.119% |
| Intervacc AB (publ) | -102.85 Million SEK | 83.935% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 93.353% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -3672.374% |
| Corline Biomedical AB | -1.8 Million SEK | -813.378% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 90.709% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 70.921% |
| Aptahem AB (publ) | -11.11 Million SEK | -48.683% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 86.574% |
| Fluicell AB (publ) | -26.55 Million SEK | 37.776% |
| Biovica International AB (publ) | -124.82 Million SEK | 86.763% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 60.867% |
| Abliva AB (publ) | -95.5 Million SEK | 82.7% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 94.946% |
| 2cureX AB (publ) | -32.51 Million SEK | 49.188% |
| I-Tech AB | 20.2 Million SEK | 181.785% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.013% |
| Cyxone AB (publ) | -22.98 Million SEK | 28.126% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 81.923% |
| Biosergen AB | -27.03 Million SEK | 38.887% |
| Nanologica AB (publ) | -75.15 Million SEK | 78.015% |
| SynAct Pharma AB | -215.81 Million SEK | 92.344% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 62.494% |
| BioInvent International AB (publ) | -330.3 Million SEK | 94.998% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 30.391% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 93.367% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -66.395% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 84.881% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -41.488% |